Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $147,285.00 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Ingrid Delaet sold 1,091 shares of the company’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total value of $147,285.00. Following the sale, the insider now owns 2,507 shares in the company, valued at approximately $338,445. This represents a 30.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Neurocrine Biosciences Trading Down 0.4 %

Neurocrine Biosciences stock traded down $0.49 during mid-day trading on Thursday, hitting $134.96. The stock had a trading volume of 983,037 shares, compared to its average volume of 878,463. The firm has a market capitalization of $13.66 billion, a P/E ratio of 36.18 and a beta of 0.34. Neurocrine Biosciences, Inc. has a one year low of $110.95 and a one year high of $157.98. The firm’s 50 day moving average is $123.14 and its 200 day moving average is $130.61.

Hedge Funds Weigh In On Neurocrine Biosciences

Institutional investors have recently bought and sold shares of the stock. State Street Corp lifted its stake in Neurocrine Biosciences by 11.7% in the third quarter. State Street Corp now owns 5,148,293 shares of the company’s stock worth $593,186,000 after purchasing an additional 539,936 shares during the last quarter. 1832 Asset Management L.P. boosted its position in Neurocrine Biosciences by 1,370.7% during the second quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company’s stock valued at $74,507,000 after purchasing an additional 504,400 shares in the last quarter. Los Angeles Capital Management LLC boosted its stake in Neurocrine Biosciences by 639.6% in the third quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock valued at $48,479,000 after acquiring an additional 363,863 shares in the last quarter. AQR Capital Management LLC boosted its holdings in Neurocrine Biosciences by 23.0% in the second quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock worth $166,959,000 after acquiring an additional 228,444 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in Neurocrine Biosciences by 9.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock worth $339,790,000 after purchasing an additional 216,500 shares during the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on NBIX shares. William Blair reissued an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research report on Monday, November 11th. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, September 16th. BMO Capital Markets lowered their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research note on Thursday, October 17th. Finally, StockNews.com cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Five research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $166.00.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.